Biogen Idec to present new neurology data at AAN 2012 meeting Zenopa New data will highlight the safety and efficacy of the marketed products Tysabri, Avonex and Fampyra, as well as results from investigational trials of key late-stage compounds such as BG-12, PEGylated interferon beta-1a and daclizumab high-yield ... BIOGEN IDEC INC. : New Data Presented at 64th AAN Annual Meeting Highlights ... |
